Teva Pharma (TEVA) Tops Q1 EPS by 4c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.52, $0.04 better than the analyst estimate of $0.48. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.98 billion.
GUIDANCE:
Teva Pharma sees FY2025 EPS of $2.45-$2.65, versus the consensus of $2.56. Teva Pharma sees FY2025 revenue of $16.8-17.2 billion, versus the consensus of $17.243 billion.
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
- Intel shares fall as competitor reports record results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
